NCT06874283 Ocular Complications From Cancer Therapy - Patient Registry and Biobank
| NCT ID | NCT06874283 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Maryland, Baltimore |
| Condition | Graft Versus Host Disease in Eye |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-05-13 |
| Primary Completion | 2031-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2025-05-13 with a primary completion date of 2031-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to collect data on patients seen at University of Maryland after undergoing cancer therapy. Previous medications, ocular history, medical history, clinical evaluations, surgical procedures and outcomes will be gathered on the patients who consent to participate. Potential subjects will be enrolled from the clinical practice of the investigator at the time of their eye examination visit. A standard of care exam will be performed pertinent to the reason for the visit. In addition to the standard of care exam, certain biological specimens (ocular surface wash, mucocellular material, corneal filaments, impression cytology, and/or blood) will be collected, stored, and analyzed to obtain immunologic, cellular, or molecular mechanistic insights into disease pathogenesis.
Eligibility Criteria
Inclusion Criteria for the Cancer Therapy Group: * Adult patients (greater than 18 years of age) * Deny a history of eye diseases (excluding cataract, glaucoma, mild dry eye disease, or history of cataract or refractive surgery) * Patients who have a history of allogenic HSCT with all stem cell sources including bone marrow, PBSC, cord AND/OR patients with a history of prior cancer therapy including BMT, chemotherapy, and immunotherapy * Patients will be recruited after their HSCT or cancer therapy at their ophthalmology appointment * Patients can be included with a history of prior cancer therapy including chemotherapy, BMT, immunotherapy. Prior cancer therapy must be identified and documented. * The patient must be able to understand and sign and date the informed consent form approved by the IRB. Inclusion Criteria for the Control Group: * No history of cancer or cancer therapy in the past * Adult patients (greater than 18 years of age) * Deny a history of eye diseases (excluding cataract, glaucoma, mild dry eye disease, or history of cataract or refractive surgery) * The patient must be able to understand and sign and date the informed consent form approved by the IRB. Exclusion Criteria for the Cancer Therapy Group: * Vulnerable populations: neonates, children, prisoners, institutionalized individuals * Inability or refusal to provide informed consent. * History of ocular surgery or ocular disease (except refractive or cataract surgery, mild dry eye disease, or glaucoma). Exclusion Criteria for the Control Group: * Vulnerable populations: neonates, children, prisoners, institutionalized individuals * Inability or refusal to provide informed consent. * History of ocular surgery or ocular disease (except refractive or cataract surgery, mild dry eye disease, or glaucoma). * History of cancer or cancer therapy including chemotherapy, immunotherapy, BMT.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06874283 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Graft Versus Host Disease in Eye. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06874283 currently recruiting?
Yes, NCT06874283 is actively recruiting participants. Contact the research team at ssunshine@som.umaryland.edu for enrollment information.
Where is the NCT06874283 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT06874283 clinical trial?
NCT06874283 is sponsored by University of Maryland, Baltimore. The trial plans to enroll 150 participants.